Figure 1. MTBITC selectively kills liver tumor cells.

MTBITC treatment selectively attenuates cell survival of liver tumor cells (a) as compared to primary hepatocytes (b). Cell viability was assessed using the NR retention assay after exposure to MTBITC for 24–72 h. Results were expressed relative to control (0.1% DMSO), bars are mean+SD, (number of independent experiments is given below the figures). Positive control (+), 0.01% Triton X-100. ** ≤p<0.01 compared to DMSO.